{'fraction_non_alphanumeric': 0.03239929947460595, 'fraction_numerical': 0.0148861646234676, 'mean_word_length': 4.891752577319588, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Initial Results of Hypofractionated Carbon Ion Radiotherapy for Cholangiocarcinoma.

AIM
To report initial results of hypofractionated carbon ion radiotherapy (C-ion RT) for cholangiocarcinoma.


PATIENTS AND METHODS
Data regarding seven patients with cholangiocarcinoma treated by C-ion RT were analyzed. Prescribed doses were 52.8 Gy [relative biological effectiveness (RBE)] or 60.0 Gy (RBE) in four fractions for intrahepatic cases and 12 fractions for hilar hepatic/close to gastro-intestinal tract cases. Local control and overall survival were evaluated and toxicity was graded using Common Terminology Criteria for Adverse Events, version 4.0.


RESULTS
The median follow-up period was 16 months. There were two patients with stage I cancer, one with stage II, one with stage III, and three with stage IVA. Local control was achieved in five out of seven patients (71%) and survival was maintained in six out of seven patients (86%). There were no occurrences of acute or late toxicity of grade 3 or higher.


CONCLUSION
Initial results show that hypofractionated C-ion RT appears to be tolerated and effective for cholangiocarcinoma.